Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

285 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, Tolcher AW. Mita MM, et al. Ann Oncol. 2006 Feb;17(2):313-21. doi: 10.1093/annonc/mdj067. Epub 2005 Dec 1. Ann Oncol. 2006. PMID: 16322117 Clinical Trial.
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.
de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW. de Bono JS, et al. Ann Oncol. 2004 Dec;15(12):1825-33. doi: 10.1093/annonc/mdh472. Ann Oncol. 2004. PMID: 15550589 Clinical Trial.
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK. Tolcher AW, et al. Br J Cancer. 2003 Apr 7;88(7):1004-11. doi: 10.1038/sj.bjc.6600827. Br J Cancer. 2003. PMID: 12671695 Free PMC article.
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Britten CD, Rowinsky EK, Soignet S, Patnaik A, Yao SL, Deutsch P, Lee Y, Lobell RB, Mazina KE, McCreery H, Pezzuli S, Spriggs D. Britten CD, et al. Clin Cancer Res. 2001 Dec;7(12):3894-903. Clin Cancer Res. 2001. PMID: 11751480 Clinical Trial.
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK. Hidalgo M, et al. J Clin Oncol. 2001 Jul 1;19(13):3267-79. doi: 10.1200/JCO.2001.19.13.3267. J Clin Oncol. 2001. PMID: 11432895 Clinical Trial.
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Villalona-Calero MA, Blum JL, Jones SE, Diab S, Elledge R, Khoury P, Von Hoff D, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Rowinsky EK. Villalona-Calero MA, et al. Ann Oncol. 2001 May;12(5):605-14. doi: 10.1023/a:1011181010669. Ann Oncol. 2001. PMID: 11432617 Clinical Trial.
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Tolcher AW, Eckhardt SG, Kuhn J, Hammond L, Weiss G, Rizzo J, Aylesworth C, Hidalgo M, Patnaik A, Schwartz G, Felton S, Campbell E, Rowinsky EK. Tolcher AW, et al. J Clin Oncol. 2001 Jun 1;19(11):2937-47. doi: 10.1200/JCO.2001.19.11.2937. J Clin Oncol. 2001. PMID: 11387367 Clinical Trial.
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson J Jr, Schwartz G, Patnaik A, Smith L, Molpus K, Felton S, Gupta E, Ferrante KJ, Tortora A, Sonnichsen DS, Skillings J, Rowinsky EK. Hidalgo M, et al. J Clin Oncol. 2001 May 1;19(9):2493-503. doi: 10.1200/JCO.2001.19.9.2493. J Clin Oncol. 2001. PMID: 11331328 Clinical Trial.
285 results
Jump to page